Cite
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
MLA
Richardson, Paul G., et al. “The Potential Benefits of Participating in Early-Phase Clinical Trials in Multiple Myeloma: Long-Term Remission in a Patient with Relapsed Multiple Myeloma Treated with 90 Cycles of Lenalidomide and Bortezomib.” European Journal of Haematology, vol. 88, no. 5, May 2012, pp. 446–49. EBSCOhost, https://doi.org/10.1111/j.1600-0609.2012.01765.x.
APA
Richardson, P. G., Laubach, J. P., Schlossman, R. L., Ghobrial, I. M., Redman, K. C., Mckenney, M., Warren, D., Noonan, K., Lunde, L., Doss, D., Colson, K., Hideshima, T., Mitsiades, C., Munshi, N. C., & Anderson, K. C. (2012). The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. European Journal of Haematology, 88(5), 446–449. https://doi.org/10.1111/j.1600-0609.2012.01765.x
Chicago
Richardson, Paul G., Jacob P. Laubach, Robert L. Schlossman, Irene M. Ghobrial, Katherine C. Redman, Mary Mckenney, Diane Warren, et al. 2012. “The Potential Benefits of Participating in Early-Phase Clinical Trials in Multiple Myeloma: Long-Term Remission in a Patient with Relapsed Multiple Myeloma Treated with 90 Cycles of Lenalidomide and Bortezomib.” European Journal of Haematology 88 (5): 446–49. doi:10.1111/j.1600-0609.2012.01765.x.